- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Walgreens expands preventive healthcare services to Maryland market
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- PhRMA report lists 271 vaccines in development
SAN FRANCISCO — Drug maker Bristol-Myers Squibb and the Gladstone Institutes will collaborate to find new ways to treat Alzheimer's disease, the two said Thursday.
Gladstone's research will focus on dysfunction of the Tau protein. The protein regulates the internal structure of cells and is thought to also regulate brain cell activity, but in Alzheimer's patients, it forms abnormal deposits called neurofibrillary tangles, a hallmark pathology of the disease. By identifying ways to reverse Tau dysfunction, Bristol and Gladstone hope to develop new drugs to modify the disease's course.
"Bristol-Myers Squibb is committed to helping patients address the unmet medical need for effective treatments across the Alzheimer's disease continuum, from predementia to severe disease, by developing and studying a broad and diversified portfolio of compounds directed at multiple pathologies and different mechanisms," Bristol SVP discovery Francis Cuss said.